Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Mykhailo Ihnatenko
Mykhailo Ihnatenko

Haemonetics announces second quarter fiscal 2027 results: Can HAE break above $128.72?

Haemonetics announces second quarter fiscal 2027 results: Can HAE break above $128.72?
Haemonetics stock rises 5.9% today

Haemonetics Corporation posted second quarter fiscal 2027 results on its investor website. The stock is up 5.9% on the day at $127.42.

Highlights

  • Haemonetics Corporation announced second quarter fiscal 2027 results for the period ended September 26, 2026, with trailing revenue of $1.35 billion.
  • Haemonetics stock is up 5.9% on the day at $127.42 and carries a market value near $4.69 billion.
  • 34 of 44 covering analysts rate Haemonetics stock a buy, and the most recent price target is $140.

Haemonetics Corporation announced that its second quarter fiscal 2027 financial results are now available on the company Investor Relations website. The figures cover the quarter ended September 26, 2026, PR Newswire reported. Haemonetics operates in the medical devices sector and reported trailing revenue of $1.35 billion.

Bullish bias holds as overbought RSI limits further upside

The session began with a gap up from $120.28 to $123.25, underscoring firm buying interest. Price remains above its MA-20, MA-50, and MA-200, with the broader daily structure staying bullish. The nearest resistance is the weekly high at $128.72. RSI at 74.5 is in overbought territory, a stretched reading that limits room for further upside.

Upside odds remain strong as traders watch $128.72 resistance

Traders should monitor whether shares can close above the weekly high at $128.72 to confirm buyers' conviction. The opening move jumped from $120.28 to $123.25, highlighting strong upward momentum. Even so, for the coming trading week, the probability of further upside is more than 80%, while the risk of a downside move is less than 20%, with an expected trading range between $122.79 and $132.04. A drop below $119.78 would indicate the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Haemonetics maintained a broadly bullish technical structure supported by regulatory approval news. The current earnings-driven price surge further reinforces this constructive outlook, with traders advised to watch performance near $128.72 as a key resistance level for signs of further continuation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Buterin’s new vision: Why Ethereum wants to become digital gold
  • By Olena Litvinenko
  • 1 hour ago
Buterin’s new vision: Why Ethereum wants to become digital gold
Editors' Picks
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • By Anastasiia Chabaniuk
  • 5 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
Editors' Picks
Shield AI’s Echodyne deal and the global counter-drone race
  • By Dmytro Kharkov
  • 6 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
Editors' Picks
All Editors' Top Picks

Latest Haemonetics News

Haemonetics marks U.S. launch of PerQseal Elite after stock ends session down 3.3%
  • By Viktoras Karapetjanc
  • 10 min ago
Haemonetics marks U.S. launch of PerQseal Elite after stock ends session down 3.3%
Companies
#Haemonetics
Haemonetics announces FDA approval of PerQseal Elite: Will HAE hold $118.33 support?
  • By Ciaran Ryan
  • 19.10.2026
Haemonetics announces FDA approval of PerQseal Elite: Will HAE hold $118.33 support?
Companies
#Haemonetics
Haemonetics stock slides 1.62 percent as price holds above key moving averages
  • By Hanna Syniavska
  • 05.08.2026
Haemonetics stock slides 1.62 percent as price holds above key moving averages
Companies
#Haemonetics
All Haemonetics News
  • Olena Litvinenko
  • 1 hour ago
Buterin’s new vision: Why Ethereum wants to become digital gold
  • Anastasiia Chabaniuk
  • 5 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • Dmytro Kharkov
  • 6 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
  • Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
  • Pavlo Kot
  • 07.11.2026
Apartment or Bitcoin: Choosing a safe haven for your wealth
  • Eugene Komchuk
  • 1 min ago
Patrick Karim: Oil typically sells at a premium to silver on yearly or quarterly closes
  • Daria Chernytska
  • 2 min ago
Stock market concentration is high as top 10 S&P stocks reach 40 percent share, Ben Carlson notes
  • Pavlo Kot
  • 5 min ago
Cfosilvia offers partner account access, Anthony Pompliano notes
  • Alena Volkova
  • 20 min ago
Shay Boloor: Iridium signs MOU with Vodafone Qatar amid Gulf GPS interference concerns
  • Yulia Slavina
  • 24 min ago
AI proves to be an engine of job growth, Mark Zandi notes
Top News
  • Eugene Komchuk
  • 1 hour ago
Hedge funds begin massive selloff of technology stocks
Hedge funds begin massive selloff of technology stocks
  • Oleg Tkachenko
  • 3 hours ago
U.S. authorities grant Coinbase a banking charter
U.S. authorities grant Coinbase a banking charter
  • Olga Shendetskaya
  • 4 hours ago
Oil prices fall after Trump's comments on Iran
Oil prices fall after Trump's comments on Iran
  • Pavlo Kot
  • 6 hours ago
Binance, Tether and Trump-linked crypto firms face congressional scrutiny
Binance, Tether and Trump-linked crypto firms face congressional scrutiny
  • Dmytro Kharkov
  • 6 hours ago
Shield AI’s Echodyne deal and the global counter-drone race
Shield AI’s Echodyne deal and the global counter-drone race
Live News
  • Mélissa Bac
  • Now
Strategy buys $82 million in Bitcoin, raises holdings to 850,364 BTC
  • Mykhailo Ihnatenko
  • Now
Nvidia stock falls amid CEO scrutiny: Can buyers reclaim $178?
  • Anton Kharitonov
  • Now
EUR/USD targets 1.1200 as dollar weakens ahead of U.S. inflation data
  • Mykhailo Ihnatenko
  • Now
Ethereum slides as geopolitical risks trigger another $1B liquidation wave
  • Pavlo Kot
  • Now
Binance hackers still hold $3.1 billion in cryptocurrency after attack
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers